HTL0039732 (also known as NXE0039732) is Nxera's novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK's Centr ...

Addition of the PCSK9 inhibitor evolocumab to statin therapy after CABG surgery does not improve 24-month graft patency, in ...

FDA clearance confirms robust safety and performance of VCFix® Spinal System, a breakthrough treatment for vertebral compression fracturesUS commercial ...

Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg ...

A bout of the common bladder infection, cystitis, may signal the presence of urogenital cancers-which affect parts of the body involved in reproduction and excretion-in middle aged adults, suggests ...

Kidney injury molecule–1 (KIM-1) has emerged as a potential prognostic biomarker for response to therapy and could be used to ...

New research indicates that individuals living with dementia are being treated with potent antipsychotic medications for ...

A bout of the common bladder infection, cystitis, may signal the presence of urogenital cancers—which affect parts of the ...

Fasting and ketogenic diets were found to benefit blood fats, weight, and blood pressure in MS, but did not reduce brain ...

TransMedics' growth is set to remain robust over the next 12 months, supported by its heart and lung clinical trials. Click ...

CBT-I Is the evidence-based first-line treatment, but access gaps persist.

A drug called riluzole, commonly used to treat amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, could ...